SCHEMBL7253697

SCHEMBL7253697

Fc1cnc(Cl)nc1-c1cccc(C(F)(F)F)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 2/20 0.46
ADORA1 P30542 2/20 0.46
TDP1 Q9NUW8 1/20 0.45
SCN2A Q99250 2/20 0.44
JUN P05412 1/20 0.44
NFKB1 P19838 1/20 0.44
NFKB2 Q00653 1/20 0.44
RELA Q04206 1/20 0.44
DYRK1A Q13627 2/20 0.44
DYRK2 Q92630 2/20 0.44
CCNA2 P20248 1/20 0.44
CDK2 P24941 1/20 0.44
CDK5 Q00535 1/20 0.44
CDK5R1 Q15078 1/20 0.44
DYRK1B Q9Y463 1/20 0.44
RORB Q92753 2/20 0.44
HRH1 P35367 1/20 0.44
HRH4 Q9H3N8 1/20 0.44
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15577176 0.81 BTK (0.46) ADORA2AADORA1KDM4EMEN1ALDH1A1
SCHEMBL19078912 0.80 MAPT (0.42) ADORA2AADORA1JUNNFKB1NFKB2
SCHEMBL31334102 0.80 MAPT (0.42) ADORA2AADORA1JUNNFKB1NFKB2
SCHEMBL13120752 0.79 BIRC5 (0.42) HRH1HRH4MEN1ALDH1A1HPGD
SCHEMBL31333468 0.78 BTK (0.38) ADORA1CYP1A2CYP3A4CYP2C9
SCHEMBL31333278 0.78 JUN (0.40) JUNNFKB1NFKB2RELAMEN1
SCHEMBL3758203 0.77 KDM4E (0.52) ADORA2AADORA1JUNNFKB1NFKB2
SCHEMBL7216188 0.77 ADORA2A (0.60) ADORA2AADORA1TDP1SCN2AJUN
SCHEMBL1467372 0.75 ALDH1A1 (0.47) JUNNFKB1NFKB2RELADYRK1A
SCHEMBL15577238 0.75 CLK4 (0.46) ADORA2AADORA1IDO1ATR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2003030909-A1 2- AND 4-AMINOPYRIMIDINES N-SUBSTTITUDED BY A BICYCLIC RING FOR USE AS KINASE INHIBITORS IN THE TREATMENT OF CANCER BAYER PHARMACEUTICALS CORPORATION (US) 2003-04-17 WO disclosed